Natriumjodid (I-131) Curiumpharma (Sodium Iodide (131i))

Sodium Iodide I-131, the active ingredient in Natriumjodid (I-131) Curiumpharma, is a radioactive iodine presented as an oral solution for oral use. It is employed in the management of hyperthyroidism, thyroid cancer and for thyroid tissue ablation in adult patients.

GNH USA supplies Natriumjodid (I-131) Curiumpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation to support import and clinical use.

Natriumjodid (I-131) is a radioactive iodine used in the thyroid disease treatment pathway.

- Hyperthyroidism: reduces thyroid hormone production by destroying overactive thyroid cells, helping to achieve euthyroidism. - Thyroid cancer: eliminates residual thyroid tissue after thyroidectomy, improving disease control and facilitating postoperative monitoring. - Thyroid ablation: prepares patients for diagnostic radioactive iodine scanning or reduces thyroid tissue prior to other therapeutic interventions, enhancing treatment precision.

Oral administration of sodium iodide I-131 may be associated with a range of adverse reactions.

Common Side Effects: - Nausea - Vomiting - Dry mouth - Altered taste perception - Neck tenderness - Mild fever

Serious or Rare Side Effects: - Severe hypothyroidism - Radiation thyroiditis - Bone marrow suppression - Anaphylactic allergic reaction - Pulmonary fibrosis (very rare)

Before prescribing Natriumjodid (I-131), clinicians should consider several safety measures. - Pregnancy: avoid use unless clearly needed, as fetal thyroid may be affected. - Breastfeeding: discontinue breastfeeding during treatment and for a defined period after. - Thyroid function: assess baseline thyroid hormone levels before administration. - Concurrent thyroid medication: adjust antithyroid drugs as they may reduce iodine uptake. - Radiation safety: follow local regulations for handling and disposal of radioactive material. - Store at ambient temperature: keep in original container, protect from moisture and light.

Natriumjodid (I-131) can interact with several medications and substances that influence iodine metabolism.

Major Interactions (Avoid): - Antithyroid drugs (e.g., methimazole, propylthiouracil) reduce iodine uptake. - Lithium therapy interferes with thyroid function and iodine uptake. - High dietary iodine (iodine supplements, contrast agents) decreases effectiveness.

Moderate Interactions (Monitor Closely): - Levothyroxine may require dose adjustment after ablation. - Corticosteroids can affect radiation response. - Certain chemotherapy agents may increase bone marrow toxicity.